The short version of Limit of detection fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
Method validation establishes that an HPLC procedure is suitable for its intended use. Key parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Accuracy measures agreement with a true or accepted value, while precision describes repeatability and intermediate precision. Specificity confirms that the method measures the analyte without interference from impurities, degradants, or excipients. Validation is documented in a protocol and report, and acceptance criteria are set before experiments begin. Regulatory guidance varies by region, but the general principles are widely harmonized.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Common checks include retention time, peak area, resolution between critical pairs, tailing factor, and theoretical plate count. Results are compared with predefined limits, and a failed check requires investigation before sample results are reported. Quality control samples at low, middle, and high concentrations are injected at intervals to monitor accuracy and precision. Blank injections detect carryover and contamination, while control charts track performance over time.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
In quality control laboratories, HPLC testing supports batch release, raw material checks, stability studies, and impurity profiling. A validated method defines sample preparation, instrument settings, calibration, and acceptance criteria. Analysts compare results with specifications and investigate out-of-specification outcomes before a batch is approved. Documentation includes chromatograms, integration records, audit trails, and reagent details. Because results influence product decisions, laboratories follow formal quality systems and data integrity rules. The exact tests and limits depend on the material, its intended use, and the applicable regulatory framework.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
| Property | Value | Notes |
|---|---|---|
| Validation parameter | Accuracy | Measured value compared with true or accepted value |
| Precision type | Repeatability | Same analyst, instrument, and short time interval |
| Linearity range | 50–150% of target concentration | Common for assay methods; method-dependent |
| Limit of quantitation | Signal-to-noise ratio of 10:1 | Lowest concentration with acceptable precision |
| Common synonyms | Method validation, analytical validation | Documented confirmation that a method is suitable |
Validation demonstrates that a method is suitable for its intended use. Typical performance characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulators and standards organizations provide frameworks, but specific requirements depend on the application and jurisdiction. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, retention time repeatability, and sensitivity. A validated method is not permanently fixed; changes may require partial or full revalidation.
Routine HPLC testing depends on controlled reagents, calibrated instruments, and documented procedures. Columns degrade over time, so retention times and peak shapes are monitored for drift. Mobile phases are filtered and degassed to prevent pump damage and detector noise. Reference standards must be traceable and stored under suitable conditions. Data handling systems record injections, calculations, and audit trails. Quality control samples interspersed with unknowns help detect errors during a run.
Routine quality control includes blanks, duplicates, spiked samples, and certified reference materials. Calibration curves are prepared with standards at several concentrations, and the detector response is checked for linearity. Carryover, column aging, mobile phase evaporation, and temperature drift can shift retention times or peak areas. Maintenance such as replacing seals, filters, and columns helps prevent failures. Records of injections, integration, and deviations support traceability. Audits may request raw data and instrument logs for each batch.
Developing an HPLC test begins with defining the analytes, matrix, and required reporting limits. Chemists select a separation mode, column chemistry, mobile phase composition, flow rate, and detection wavelength or mass transition. Experiments then adjust these variables to achieve adequate retention, resolution, and peak shape. System suitability tests confirm that the instrument and method perform consistently before sample analysis. Without suitable resolution, quantitative results may be unreliable. Preliminary runs often use scouting gradients to locate retention windows.
Validation establishes that a method is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, robustness, and stability of standards and samples. Acceptance criteria are defined in advance, and results are documented in a validation report. Regulatory guidance for pharmaceuticals, foods, and environmental testing differs, so the applicable framework must be identified. Ongoing verification uses control samples and trend charts after validation. Method transfer to another laboratory may require partial revalidation.
Quality control samples are inserted at intervals to monitor accuracy and precision throughout a batch. Blank samples detect contamination, while spiked samples assess recovery from the sample matrix. Calibration standards establish the relationship between detector response and concentration, and control samples are prepared independently from them whenever possible. Laboratories also participate in proficiency testing and maintain audit trails, instrument logs, and reagent records. Ongoing review of control charts can reveal trends before they cause out-of-specification results.
Method validation demonstrates that an HPLC procedure is suitable for its intended purpose. Common validation parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, and robustness. Accuracy reflects agreement with a reference value, while precision describes repeatability under defined conditions. Specificity shows whether the method can measure the analyte in the presence of impurities or matrix components. Validation documents are reviewed before a method is used for routine testing or regulatory submissions.
Within months of the collapse of the Third Coalition, the Fourth Coalition (1806–1807) against France was formed by Britain, Prussia, Russia, Saxony, and Sweden. In July 1806, Napoleon formed the Confederation of the Rhine out of the many small German states which constituted the Rhineland and most other western parts of Germany. He amalgamated many of the smaller states into larger electorates, duchies, and kingdoms to make the governance of non-Prussian Germany smoother. Napoleon elevated the rulers of the two largest Confederation states, Saxony and Bavaria, to the status of kings. In August 1806, the Prussian king, Frederick William III, decided to go to war independently of any other great power. The army of Russia, a Prussian ally, in particular, was too far away to assist. On 8 October 1806, Napoleon unleashed all the French forces east of the Rhine into Prussia. Napoleon defeated a Prussian army at Jena (14 October 1806), and Davout defeated another at Auerstädt on the same day. 160,000 French soldiers (increasing in number as the campaign went on) attacked Prussia, moving with such speed that they destroyed the entire Prussian Army as an effective military force. Out of 250,000 troops, the Prussians sustained 25,000 casualties, lost a further 150,000 as prisoners, 4,000 artillery pieces, and over 100,000 muskets. At Jena, Napoleon had fought only a detachment of the Prussian force. The battle at Auerstädt involved a single French corps defeating the bulk of the Prussian army. Napoleon entered Berlin on 27 October 1806.
==== MeSH D06.472.699 – peptide hormones ==== MeSH D06.472.699.009 – activins MeSH D06.472.699.009.500 – inhibin-beta subunits MeSH D06.472.699.054 – adiponectin MeSH D06.472.699.100 – bombesin MeSH D06.472.699.150 – calcitonin MeSH D06.472.699.200 – corticotropin-releasing hormone MeSH D06.472.699.275 – gastric inhibitory polypeptide MeSH D06.472.699.280 – gastrins MeSH D06.472.699.318 – glucagon precursors MeSH D06.472.699.318.249 – enteroglucagons MeSH D06.472.699.318.249.500 – glucagon-like peptide 1 MeSH D06.472.699.318.500 – glucagon MeSH D06.472.699.337 – inhibins MeSH D06.472.699.337.500 – inhibin-beta subunits MeSH D06.472.699.350 – insulin MeSH D06.472.699.350.408 – insulin, isophane MeSH D06.472.699.350.532 – insulin, long-acting MeSH D06.472.699.350.788 – proinsulin MeSH D06.472.699.350.788.250 – c-peptide MeSH D06.472.699.400 – leptin MeSH D06.472.699.500 – motilin MeSH D06.472.699.560 – msh release-inhibiting hormone MeSH D06.472.699.580 – msh-releasing hormone MeSH D06.472.699.584 – natriuretic peptides MeSH D06.472.699.584.500 – atrial natriuretic factor MeSH D06.472.699.584.625 – natriuretic peptide, brain MeSH D06.472.699.584.750 – natriuretic peptide, c-type MeSH D06.472.699.587 – pancreatic polypeptide MeSH D06.472.699.590 – parathyroid hormone MeSH D06.472.699.590.850 – teriparatide MeSH D06.472.699.591 – parathyroid hormone-related protein MeSH D06.472.699.592 – peptide phi MeSH D06.472.699.595 – peptide yy MeSH D06.472.699.600 – pituitary hormone release inhibiting hormones MeSH D06.472.699.620 – pituitary hormone-releasing hormones MeSH D06.472.699.631 – pituitary hormones MeSH D06.472.699.631.525 – pituitary hormones, anterior MeSH D06.472.699.631.525.343 – gonadotropins, pituitary MeSH D06.472.699.631.525.343.288 – follicle stimulating hormone MeSH D06.472.699.631.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.699.631.525.343.288.625 – follicle stimulating hormone, human MeSH D06.472.699.631.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463 – luteinizing hormone MeSH D06.472.699.631.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463.500 – luteinizing hormone, beta subunit MeSH D06.472.699.631.525.343.583 – menotropins MeSH D06.472.699.631.525.343.583.500 – urofollitropin MeSH D06.472.699.631.525.425 – growth hormone MeSH D06.472.699.631.525.425.875 – human growth hormone MeSH D06.472.699.631.525.525 – prolactin MeSH D06.472.699.631.525.690 – pro-opiomelanocortin MeSH D06.472.699.631.525.690.130 – corticotropin MeSH D06.472.699.631.525.690.130.050 – alpha-msh MeSH D06.472.699.631.525.690.130.200 – cosyntropin MeSH D06.472.699.631.525.690.480 – lipotropin MeSH D06.472.699.631.525.690.583 – melanocyte-stimulating hormones MeSH D06.472.699.631.525.690.583.050 – alpha-msh MeSH D06.472.699.631.525.690.583.075 – beta-msh MeSH D06.472.699.631.525.690.583.115 – gamma-msh MeSH D06.472.699.631.525.883 – thyrotropin MeSH D06.472.699.631.525.883.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.883.500 – thyrotropin, beta subunit MeSH D06.472.699.631.692 – pituitary hormones, posterior MeSH D06.472.699.631.692.433 – oxytocin MeSH D06.472.699.631.692.781 – vasopressins MeSH D06.472.699.631.692.781.100 – argipressin MeSH D06.472.699.631.692.781.100.250 – deamino arginine vasopressin MeSH D06.472.699.631.692.781.400 – lypressin MeSH D06.472.699.631.692.781.400.350 – felypressin MeSH D06.472.699.631.692.781.700 – ornipressin MeSH D06.472.699.631.692.881 – vasotocin MeSH D06.472.699.649 – placental hormones MeSH D06.472.699.649.367 – chorionic gonadotropin MeSH D06.472.699.649.367.125 – chorionic gonadotropin, beta subunit, human MeSH D06.472.699.649.367.562 – glycoprotein hormones, alpha subunit MeSH D06.472.699.649.451 – gonadotropins, equine MeSH D06.472.699.649.692 – placental lactogen MeSH D06.472.699.715 – relaxin MeSH D06.472.699.762 – resistin MeSH D06.472.699.810 – secretin MeSH D06.472.699.857 – somatostatin MeSH D06.472.699.905 – urotensins MeSH D06.472.699.952 – vasoactive intestinal peptide MeSH D06.472.699.976 – vasopressins MeSH D06.472.699.976.100 – argipressin MeSH D06.472.699.976.100.250 – deamino arginine vasopressin MeSH D06.472.699.976.400 – lypressin MeSH D06.472.699.976.400.350 – felypressin MeSH D06.472.699.976.700 – ornipressin
== History == Vardenafil was co-marketed by Bayer Pharmaceuticals, GlaxoSmithKline, and Schering-Plough under the brand name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been returned to Bayer in many markets outside the US. In Italy, Bayer sells vardenafil as Levitra and GSK sells it as Vivanza. Thus, because of European Union trade rules, parallel imports might result in Vivanza sold next to Levitra in the EU. An orally disintegrating form, marketed as Staxyn and Levitra Soft, has been gaining approvals in countries such as the United States and Canada.
Sources: en.wikipedia.org
=== EC 2.8.2: Sulfotransferases === EC 2.8.2.1: aryl sulfotransferase EC 2.8.2.2: alcohol sulfotransferase EC 2.8.2.3: amine sulfotransferase EC 2.8.2.4: estrone sulfotransferase EC 2.8.2.5: chondroitin 4-sulfotransferase EC 2.8.2.6: choline sulfotransferase EC 2.8.2.7: UDP-N-acetylgalactosamine-4-sulfate sulfotransferase EC 2.8.2.8: [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.9: tyrosine-ester sulfotransferase EC 2.8.2.10: Renilla-luciferin sulfotransferase EC 2.8.2.11: galactosylceramide sulfotransferase EC 2.8.2.12: deleted, identical to EC 2.8.2.8, [heparan sulfate]-glucosamine N-sulfotransferase EC 2.8.2.13: psychosine sulfotransferase EC 2.8.2.14: bile salt sulfotransferase EC 2.8.2.15: steroid sulfotransferase EC 2.8.2.16: thiol sulfotransferase EC 2.8.2.17: chondroitin 6-sulfotransferase EC 2.8.2.18: cortisol sulfotransferase EC 2.8.2.19: triglucosylalkylacylglycerol sulfotransferase EC 2.8.2.20: protein-tyrosine sulfotransferase EC 2.8.2.21: keratan sulfotransferase EC 2.8.2.22: aryl-sulfate sulfotransferase EC 2.8.2.23: [heparan sulfate]-glucosamine 3-sulfotransferase 1 EC 2.8.2.24: desulfoglucosinolate sulfotransferase EC 2.8.2.25: flavonol 3-sulfotransferase EC 2.8.2.26: quercetin-3-sulfate 3′-sulfotransferase EC 2.8.2.27: quercetin-3-sulfate 4′-sulfotransferase EC 2.8.2.28: quercetin-3,3′-bissulfate 7-sulfotransferase EC 2.8.2.29: [heparan sulfate]-glucosamine 3-sulfotransferase 2 EC 2.8.2.30: [heparan sulfate]-glucosamine 3-sulfotransferase 3 EC 2.8.2.31: petromyzonol sulfotransferase EC 2.8.2.32: scymnol sulfotransferase EC 2.8.2.33: N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase EC 2.8.2.34: glycochenodeoxycholate sulfotransferase EC 2.8.2.35: dermatan 4-sulfotransferase EC 2.8.2.36: desulfo-A47934 sulfotransferase EC 2.8.2.37: trehalose 2-sulfotransferase EC 2.8.2.38: aliphatic desulfoglucosinolate sulfotransferase EC 2.8.2.39: hydroxyjasmonate sulfotransferase EC 2.8.2.40: ω-hydroxy-β-dihydromenaquinone-9 sulfotransferase
Following the release and favorable reviews of Last Days Here, Liebling and Pentagram experienced a significant resurgence in popularity. The documentary won multiple awards, including the Grand Jury Prize at the Independent Film Festival of Boston and Best Music Documentary at the International Documentary Film Festival Amsterdam. This renewed attention revitalized Pentagram's career, leading to international tours. Releasing a new album around the same time the documentary was published accelerated the band's resurgence. Liebling, alongside longtime collaborator Victor Griffin, returned to the studio for Last Rites, which was released in April 2011. This marked Griffin's first studio work with Pentagram in over 15 years. At the time, Liebling noted that he had written the music and lyrics for about half of the band's earlier albums, "while 30–40% were collaborations with musicians, typically guitar players". Regarding his songwriting approach for the "Last Rites", he said: "I just write the lyrics nowadays. I ran out of music. I wrote 450 songs in 30 years." In 2011, Metal Blade Records announced Pentagram's return to live performances, which included an appearance at South by Southwest and a European tour that began at the Roadburn Festival in the Netherlands. Liebling embarked on extensive touring across North America and Europe with Pentagram in the following years. However, the band continued to experience frequent lineup changes. Pentagram maintained its momentum with the release of the album Curious Volume on August 21, 2015.
ventral) side of the thorax, and the assumption that injecting venom in the prey's abdomen leads to venom dilution due to the mixing of fluids in the circulatory system and the guts; the distance where the venom has to travel to be effective also increases, making it less efficient in disabling the prey. Two other concepts have been suggested to explain the reason for prey orientation - one suggested that venom is an expensive product to produce, hence venom conservation is essential; and the other concept suggested that striking the prey in that specific position (i.e. aligning the prey as the same orientation of the centipede) would allow the centipede to sufficiently restraint the prey until the venom takes effect.
Buck O'Neil and the Negro Leagues Baseball Museum presented Helton with the Walter Fenner "Buck" Leonard Legacy Award. Helton was also given the team-honored version of the Roberto Clemente Award, for his community contributions to eastern Tennessee. Furthermore, he was the NL winner of the second annual Hank Aaron Award. Each season from 2000 to 2003, he was named the Rockies Player of the Year. Capitalizing on his success, Helton signed a nine-year, $141.5 million contract in April 2001, which took effect after his then-contract expired after 2002. That season, Helton hit a career-high 49 home runs (22 of them occurred away from hitter-friendly Coors Field). He tied Walker for the most home runs ever by a Rockies player in one season. Additionally, Helton had a .336/.432/.685 slash line. He had 105 extra base hits, making him the first player in MLB history to have at least 100 total extra base hits in back-to-back seasons. Furthermore, Helton attained 402 total bases, making him only the fourth player in MLB history to do so in consecutive seasons (Chuck Klein, Gehrig and Foxx are the others). Helton appeared in his second consecutive All-Star Game in 2001 — his first as a starter. He won his first Gold Glove at first base and was once again a top candidate for MVP, but was beaten in balloting by Sammy Sosa and Barry Bonds. In 2002, Helton had a .329 batting average, 30 home runs, 109 RBI, 98 walks, 107 runs, .577 SLG and 319 total bases. He became the first player in Rockies history to score at least 100 runs in four consecutive seasons.
Sources: en.wikipedia.org
System suitability is a set of checks that confirm the instrument and method perform within limits before sample analysis. It typically includes resolution, tailing factor, retention time, and peak area reproducibility. If a check fails, the run is invalidated until the cause is resolved.
QC samples are usually injected at the beginning, at intervals during the run, and at the end. The exact frequency depends on the method, sample count, and regulatory requirements. Results outside acceptance limits can require rejection of the affected samples and investigation.
Method validation demonstrates that an HPLC procedure produces reliable results for its intended purpose. It provides documented evidence for accuracy, precision, specificity, and other performance characteristics. Regulators and quality systems require validation before a method is used for release or stability testing.
System suitability is a set of checks performed before and during an HPLC run to confirm that the instrument and method are working as expected. It may include retention time repeatability, resolution between peaks, peak symmetry, and signal intensity. Failing suitability criteria usually invalidates the run.